经直肠超声引导下前列腺穿刺活检联合前列腺抗原诊断前列腺癌中的价值  

Value of transrectal ultrasound-guided prostate biopsy combined with prostate antigen in the diagnosis of prostate cancer

作　　者：程娟 徐健[2] 唐黎明[3] CHENG Juan;XU Jian;TANG Liming(Department of Ultrasound,Chongqing Municipal Occupational Disease Prevention and Treatment Hospital, Chongqing Sixth Peopler's Hospital,Chongqing 400060, China;Department of Ultrasound, Banan District Peopler's Hospital, Chongqing 401320, China;Department of Urology,the 169 Hospital of Peopler's Liberation Army,Hengyang 421002,Hunan,China)

机构地区：[1]重庆市职业病防治院(重庆市第六人民医院)超声科,重庆400060 [2]重庆市巴南区人民医院超声科,重庆401320 [3]中国人民解放军第一六九医院泌尿外科,湖南衡阳421002

出　　处：《中国性科学》2019年第4期5-7,共3页Chinese Journal of Human Sexuality

基　　金：湖南省卫生计生委2017年度科研计划课题项目(C2017023)

摘　　要：目的分析经直肠超声引导下前列腺穿刺活检联合血清前列腺抗原检测对前列腺癌的诊断价值。方法选取2016年1月至2017年12月重庆市职业病防治院、巴南区人民医院诊治的100例前列腺癌患者的临床资料进行回顾性分析。所有患者入院后均行直肠超声引导下前列腺穿刺活检及血清前列腺特异抗原检测。对比分析两种方法及联合诊断对诊断前列腺癌的灵敏度、特异度、阳性预测值、诊断符合率等指标。结果①72例确诊前列腺癌患者,联合诊断灵敏度为87.50%,穿刺活检灵敏度为76.39%,血清前列腺特异性抗原灵敏度为70.83%。联合诊断与穿刺活检相比差异具有统计学意义(P<0.05),联合诊断与前列腺特异性抗原相比差异具有统计学意义(P<0.05)。②28例确诊为非前列腺癌患者,联合诊断特异度为78.57%,穿刺活检特异度为67.86%,血清前列腺特异性抗原特异度为78.57%。联合诊断与穿刺活检相比差异具有统计学意义(P<0.05),联合诊断与前列腺特异性抗原相比差异无统计学意义(P>0.05)。③联合诊断诊断符合率为85.00%,而穿刺活检诊断率为74.00%,血清前列腺特异性抗原诊断率为73.00%。联合诊断与穿刺活检及前列腺特异性抗原相比差异均无统计学意义(均P>0.05)。结论经直肠超声引导下前列腺穿刺活检联合血清前列腺抗原检测对诊断前列腺癌的灵敏度、特异度、诊断符合率明显高于单独应用其中一种方法。联合诊断的漏诊率较低、阳性预测值上差异不大。联合针对前列腺癌有较高的诊断价值。Objective To analyze the diagnostic value of transrectal ultrasound-guided prostate biopsy and detection of serum prostate antigen in the diagnosis of prostate cancer. Methods A retrospective analysis of the clinical data of 100 patients with prostate cancer from January 2016 to December 2017 was conducted. All the patients underwent transrectal ultrasound-guided prostate biopsy and detection of serum prostate specific antigen after admission. The sensitivity, specificity, positive predictive value and diagnostic coincidence rate of the two methods and combined diagnosis of prostate cancer were compared and analyzed. Results ①In 72 patients with confirmed prostate cancer, the combined diagnostic sensitivity was 87.50%, the sensitivity of needle biopsy was 76.39%, and the sensitivity of serum prostate specific antigen was 70.83%. The difference between the combined diagnosis and the biopsy was statistically significant(P<0.05). The difference between the combined diagnosis and prostate specific antigen was statistically significant(P<0.05).②Among the 28 patients diagnosed non-prostatic cancer, the specificity of combined diagnosis, transrectal ultrasound-guided prostate biopsy and detection of serum prostate specific antigen was 78.57%, 67.86% and 78.57% respectively, with statistically significant differences between combined diagnosis and transrectal ultrasound-guided prostate biopsy(P<0.05) and no significant difference between combined diagnosis and detection of serum prostate specific antigen(P>0.05).③The diagnostic coincidence rate of combined diagnosis, transrectal ultrasound-guided prostate biopsy and detection of serum prostate specific antigen was 85.00%, 74.00% and 73.00% respectively, without statistically significant differences among the three groups(P>0.05). Conclusions The sensitivity, specificity and diagnostic coincidence rate of transrectal ultrasound-guided prostate biopsy and detection of serum prostate antigen in the diagnosis of prostate cancer are significantly higher than those of si

关 键 词：经直肠超声 前列腺特异性抗原 前列腺癌 

分 类 号：R698[医药卫生—泌尿科学]